Optimizing treatment for patients with anaplastic lymphoma kinase-positive lung cancer.
In the 9 years since the initial discovery of anaplastic lymphoma kinase (ALK) gene rearrangements in non-small cell lung cancer (NSCLC), there has been tremendous progress, culminating in an ever-expanding repertoire of agents that have activity in this disease. This review article provides an overview of currently approved ALK inhibitors, other ALK inhibitors in development, and commonly described mechanisms of resistance to ALK inhibitors. We also discuss emerging controversies in treatment of patients with ALK-positive lung cancer, including the choice of first-line ALK inhibitor and the role of tyrosine kinase inhibitors in the treatment of central nervous system metastases.
Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
I
I
Dagogo-Jack
Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
A T
AT
Shaw
Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York, USA.
G J
GJ
Riely
D000077548:Anaplastic Lymphoma Kinase; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D017728:Lymphoma, Large-Cell, Anaplastic / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D057285:Precision Medicine; D011379:Prognosis; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000235:genetics
D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; C000626173:ALK protein, human; D000077548:Anaplastic Lymphoma Kinase; D020794:Receptor Protein-Tyrosine Kinases